TrialCancer2011

Phase 1b-2a study to reverse platinum resistance through use of a hypomethylating agent, azacitidine, in patients with platinum-resistant or platinum-refractory epithelial ovarian cancer.

Siqing Fu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.